Cargando…
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738103/ https://www.ncbi.nlm.nih.gov/pubmed/31350526 http://dx.doi.org/10.1038/s41416-019-0528-0 |
| _version_ | 1783450784607764480 |
|---|---|
| author | Gorbunova, Vera Beck, J. Thaddeus Hofheinz, Ralf-Dieter Garcia-Alfonso, Pilar Nechaeva, Marina Gracian, Antonio Cubillo Mangel, Laszlo Fernandez, Elena Elez Deming, Dustin A. Ramanathan, Ramesh K. Torres, Alison H. Sullivan, Danielle Luo, Yan Berlin, Jordan D. |
| author_facet | Gorbunova, Vera Beck, J. Thaddeus Hofheinz, Ralf-Dieter Garcia-Alfonso, Pilar Nechaeva, Marina Gracian, Antonio Cubillo Mangel, Laszlo Fernandez, Elena Elez Deming, Dustin A. Ramanathan, Ramesh K. Torres, Alison H. Sullivan, Danielle Luo, Yan Berlin, Jordan D. |
| author_sort | Gorbunova, Vera |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6738103 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67381032019-09-12 Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer Gorbunova, Vera Beck, J. Thaddeus Hofheinz, Ralf-Dieter Garcia-Alfonso, Pilar Nechaeva, Marina Gracian, Antonio Cubillo Mangel, Laszlo Fernandez, Elena Elez Deming, Dustin A. Ramanathan, Ramesh K. Torres, Alison H. Sullivan, Danielle Luo, Yan Berlin, Jordan D. Br J Cancer Correction Nature Publishing Group UK 2019-07-26 2019-08-27 /pmc/articles/PMC6738103/ /pubmed/31350526 http://dx.doi.org/10.1038/s41416-019-0528-0 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Gorbunova, Vera Beck, J. Thaddeus Hofheinz, Ralf-Dieter Garcia-Alfonso, Pilar Nechaeva, Marina Gracian, Antonio Cubillo Mangel, Laszlo Fernandez, Elena Elez Deming, Dustin A. Ramanathan, Ramesh K. Torres, Alison H. Sullivan, Danielle Luo, Yan Berlin, Jordan D. Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer |
| title | Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer |
| title_full | Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer |
| title_fullStr | Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer |
| title_full_unstemmed | Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer |
| title_short | Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer |
| title_sort | correction: a phase 2 randomised study of veliparib plus folfiri±bevacizumab versus placebo plus folfiri±bevacizumab in metastatic colorectal cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738103/ https://www.ncbi.nlm.nih.gov/pubmed/31350526 http://dx.doi.org/10.1038/s41416-019-0528-0 |
| work_keys_str_mv | AT gorbunovavera correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT beckjthaddeus correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT hofheinzralfdieter correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT garciaalfonsopilar correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT nechaevamarina correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT gracianantoniocubillo correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT mangellaszlo correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT fernandezelenaelez correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT demingdustina correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT ramanathanrameshk correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT torresalisonh correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT sullivandanielle correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT luoyan correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer AT berlinjordand correctionaphase2randomisedstudyofveliparibplusfolfiribevacizumabversusplaceboplusfolfiribevacizumabinmetastaticcolorectalcancer |